Purinergic (P2Y) Receptor
P2Y receptors are G-protein-coupled receptors that respond to extracellular purine and pyrimidine nucleotides. To date, eight mammalian P2Y receptors are known (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14) as well as the non-mammalian p2y3, p2y8 and p2y receptors.
Products for Purinergic (P2Y) Receptor - Page 3
- Cat.No. Product Name Information/Activity
-
BCC5880
MRS 2279
367909-40-8
-
BCC5881
MRS 2500 tetraammonium salt
630103-23-0
-
BCC4976
MRS 2578
MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
-
BCC7367
NF 157
NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
-
BCC7785
NF 340
202982-98-7
-
BCC6725
PPADS tetrasodium salt
PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca²⁺exchanger in guinea pig airway smooth muscle.
-
BCC6095
PSB 0739
1052087-90-7
-
BCC7079
Suramin hexasodium salt
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin sodium salt is an antitrypanosomal, anti-neoplastic and anti-angiogenic agent.
-
BCC4973
Ticlopidine HCl
Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM.
-
BCC7151
PIT
56583-49-4


